Major Depressive Disorder (MDD) Treatment Market Value Share, Supply Demand 2016-2026
Future Market Insights has announced the addition of the “Major Depressive Disorder (MDD) Treatment Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026” report to their offering.
Future Market Insights has announced the addition of the “Major Depressive Disorder (MDD) Treatment Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026” report to their offering.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Global <strong>Major</strong><br />
<strong>Depressive</strong> <strong>Disorder</strong><br />
(<strong>MDD</strong>) <strong>Treatment</strong><br />
<strong>Market</strong><br />
<strong>Share</strong>, Global Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation and Forecast,<br />
<strong>2016</strong>-<strong>2026</strong><br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and<br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports and country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive and Transportation<br />
• Electronics, Semiconductor, and ICT<br />
• Retail and Consumer Products<br />
• Industrial Automation and Equipment<br />
• Chemicals & Materials<br />
• Food and Beverages<br />
• Services and Utilities<br />
• Energy, Mining, Oil, and Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com
Report Description<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) is one of the most common mental disorder characterized by<br />
persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep<br />
and normal activities. <strong>MDD</strong> is also referred as clinical depression, major depression, and<br />
unipolar depression or as recurrent depression. The common symptoms associated with this<br />
disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of<br />
worthlessness and reduced ability to think. Increasing number of patients suffering from <strong>MDD</strong><br />
has grabbed the attention of <strong>MDD</strong> drugs manufacturer to invest into <strong>MDD</strong> treatment market.<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Drivers and Restraints<br />
Work life imbalances due to change in life style, and increase in <strong>MDD</strong> patient pool are the key<br />
drivers expected to drive the <strong>MDD</strong> treatment market over the forecasted period. Partnerships<br />
for co-development and co-marketing of <strong>MDD</strong> drugs among the drug manufactures across the<br />
globe, development of new drugs, and adequate government reimbursement policies have also<br />
fueled the growth of <strong>MDD</strong> treatment market. However, stringent regulations imposed by various<br />
governments for new drug approval, patent expiries of some blockbuster drugs, risk of<br />
complications with other medications, and related side effects of <strong>MDD</strong> drugs may hinder the<br />
growth of <strong>MDD</strong> treatment market over the forecasted period.<br />
Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1314
Report Description<br />
•<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Segmentation<br />
•The global <strong>MDD</strong> treatment market is segmented based on drug type used for the<br />
treatment of <strong>MDD</strong>.<br />
•Antidepressants<br />
• Selective Serotonin Reuptake Inhibitors (Ssris)<br />
• Dopamine Norepinephrine Reuptake Inhibitor<br />
• Serotonin Norepinephrine Reuptake Inhibitor<br />
• Serotonin Modulators<br />
• Norepinephrine-Serotonin Modulator<br />
• Tricyclics and Tetracyclics<br />
• Monoamine Oxidase Inhibitors (MAOIs)<br />
• Irreversible, non-selective inhibitors<br />
• Phenelzine<br />
• Tranylcypromine<br />
• Isocarboxazid<br />
• Irreversible, MAO B selective inhibitor<br />
• Selegiline transdermal<br />
• Reversible, MAO A selective inhibitor<br />
• Moclobemide
Report Description<br />
Atypical antidepressants<br />
Antipsychotics<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Overview<br />
At present, antidepressants are most commonly used drugs for the treatment of <strong>MDD</strong>,<br />
and has the largest market segment. <strong>Major</strong> brands of SSRI’s include Citalopram,<br />
Escitalopram, Fluoxetine, Paroxetine, and Sertraline. Bupropion, Mirtazapine, and<br />
Razodone, are atypical antidepressants frequently used for the treatment of <strong>MDD</strong>. <strong>Major</strong><br />
brands of antipsychotics includes Resperidone, Olanzapine, Quetiapine, Ziprasidone, and<br />
Aripiprazole. Global <strong>MDD</strong> treatment market is expected to grow with a healthy CAGR<br />
owing to increase in <strong>MDD</strong> patient pool over the forecast period.<br />
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1314<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Region-wise Outlook<br />
Geographically, North America market is estimated to hold maximum market revenue<br />
share in global <strong>MDD</strong> treatment market owing to increase in number of patients suffering<br />
from <strong>MDD</strong>, and advancement in technology to develop new therapeutic drugs and<br />
followed by Europe and Asia-Pacific respectivily. The market in Asia-Pacific is expected to<br />
expand at a significant CAGR over the forecasted period due to increasing awareness for<br />
depression conditions and complications associated with it. <strong>MDD</strong> treatment market is<br />
expected to register healthier CAGR in emerging markets such as India, China, and Brazil<br />
compared to other developed regions in the world.
Report Description<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Key Players<br />
Key companies operational in <strong>MDD</strong> treatment market are Eli Lilly and Company,<br />
Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc,<br />
Sanofi S.A., Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705